Thymalin

Overview

Thymalin is not a single peptide. It is a polypeptide preparation — a mixture of small peptides isolated from calf (bovine) thymus by mild acid extraction. It was developed in the Soviet Union and later Russia and is closely associated with Vladimir Khavinson and the Saint Petersburg school of "peptide bioregulators." In Russia it is registered and marketed as an immunomodulator (often called an "immunocorrector"), supplied as a lyophilized powder for injection.

Thymalin is registered in Russia — verified in the Russian State Register of Medicines (ГРЛС) under registration number LS-000267 (ЛС-000267), held by Samson-Med (St Petersburg), as a lyophilized thymus-polypeptide powder (registered composition: thymus polypeptides 10 mg + glycine 20 mg) for intramuscular injection — and has been used in some CIS countries. It is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). (Note: the registered holder is Samson-Med; the separate synthetic dipeptide Thymogen is made by a different company — the two are often conflated.)

The most important caveat about Thymalin is the nature and quality of its evidence. Most published clinical research originates from a single research group (the Khavinson/Morozov school), is predominantly Russian-language, and has seen limited independent replication in Western randomized, double-blind, placebo-controlled trials. This page describes what the literature reports while being candid about those limits.

Composition

Thymalin is produced by mild acid extraction of calf thymus tissue, yielding a fraction of small biologically active peptides. Because it is an extract, it is described as a complex or mixture rather than a defined drug substance.

Russian analytical work reports that several short peptides can be isolated from Thymalin. The immunoactive dipeptide Glu-Trp (L-Glu-L-Trp) was isolated from Thymalin and then synthesized separately as a distinct, single-peptide drug called Thymogen (Thymagen). This is an important distinction: Thymalin is the thymus extract; Thymogen is one synthetic dipeptide derived from it. They are not the same product.

Proposed mechanism

Thymalin's proposed mechanism is immunomodulatory rather than purely immunostimulatory: it is hypothesized to normalize disturbed immune parameters rather than indiscriminately boost all immune activity. Mechanisms proposed in the literature include:

• Thymic / T-cell signaling. As a thymus-derived preparation, it is proposed to support T-lymphocyte differentiation and maturation, mimicking aspects of endogenous thymic hormone activity.
• Cytokine and Th1 modulation. Reports describe enhanced Th1 cytokine production and shifts in the balance of pro- and anti-inflammatory cytokines.
• Gene-regulation hypothesis. Khavinson-group reviews propose that the short peptide components act as epigenetic regulators of gene expression, influencing synthesis of heat-shock proteins, cytokines, and proteins linked to proliferation and apoptosis.

A 2022 cell-culture study (International Journal of Molecular Sciences) tested Thymalin and related peptides (Vilon, Thymogen, Epitalon, Chonluten) on THP-1 monocyte/macrophage cells and reported that they modulated proliferation and inhibited LPS-stimulated TNF and IL-6 expression. Much mechanistic detail, however, comes from in vitro and animal work; how it translates to clinically meaningful human benefit remains the open question.

Research and evidence

Thymalin has been studied for several decades, primarily in Russia, across immune dysfunction, infections, sepsis, acute respiratory conditions, and aging. The headline results are sometimes striking, but the evidence base is heavily concentrated in one research school and is not matched by independent Western replication.

Immune dysfunction and infections

Early reviews (Morozov and Khavinson, International Journal of Immunopharmacology, 1997) describe Thymalin as a natural calf-thymus extract "put into practice as immunocorrector," used adjunctively in conditions such as influenza, viral hepatitis, herpes, and other infections, and in immune suppression after chemotherapy or radiotherapy. These are largely clinical-use reports and older trials rather than modern blinded RCTs.

COVID-19

A prospective, randomized, single-blind controlled trial at Chita State Medical Academy Hospital (Russia), reported in Advances in Gerontology (2021), enrolled 80 older patients with severe COVID-19 (36 Thymalin, 44 control). The authors reported lower hospital mortality in the Thymalin group (19.4% vs 40.9%), faster lymphocyte recovery, and reduced IL-6. This is a single-center, single-blind study with a modest sample, conducted by the developers' group; it is hypothesis-generating, not definitive. A separate single-case report (2020) described rapid improvement in one COVID-19 patient given Thymalin.

Longevity and mortality (disputed)

The most-cited and most contested result is Khavinson and Morozov's report in Neuroendocrinology Letters (2003), which followed 266 elderly people over 6–8 years and reported that Thymalin reduced mortality roughly 2.0–2.1-fold versus controls, with larger reductions when combined with the pineal preparation Epithalamin (and a reported 4.1-fold reduction with prolonged annual combined treatment). These are extraordinary claims, and the study was not a modern double-blind, placebo-controlled randomized trial; it came from the developers' own group and has not been independently replicated. Extraordinary claims of this kind require correspondingly strong, independent evidence that does not currently exist.

Russian-language primary evidence (retrieved and translated)

Much of Thymalin's primary literature is Russian-language and not indexed in the English databases most reference sites rely on. That is a limit of what those databases reach — not proof the evidence is absent. Retrieving and reading the sources directly gives a fuller, and still honest, picture. One example we pulled from the open-access Russian scientific library CyberLeninka and translated:

• [Human] A controlled comparative study in Vrach (The Physician), 2018 (Trofimova, Trofimova, Bardin) treated 49 elderly patients (aged 60–82; 26 treated, 23 control) with Thymalin (5 mg, administered by "pharmacopuncture") and reported positive psychopathological dynamics in 92.3% of the treated group, attention-task speed ~30% higher, and ~46% fewer errors versus control, with no adverse effects requiring discontinuation. Read the design carefully: it is small, non-randomized, and not blinded, uses a non-standard delivery route, comes from the same peptide-bioregulator milieu as most Thymalin work, and states no limitations of its own. It is genuine human data pointing in a direction — not a substitute for an independent randomized, blinded trial.

Two things are true at once, and honesty requires holding both: surfacing a real Russian primary source shows the literature is larger than English-only indexes suggest, and that most of it carries the design weaknesses noted throughout this page. Retrievability is not the same as high-quality evidence. What is now firmly established is the regulatory fact — the ГРЛС entry (reg. no. LS-000267, holder Samson-Med) is verifiable in the state register — while the efficacy claims remain preliminary and largely un-replicated outside their originating school.

What independent reviews say about the broader class

An independent Cochrane review of thymic peptide extracts in cancer patients (Wolf et al., 2011; 26 randomized trials, 2,736 patients) found no benefit on overall survival, disease-free survival, or tumor response, with a possible reduction in severe infectious complications. That review covered preparations such as thymostimulin and thymosin fraction 5 and did not specifically evaluate Thymalin, but it illustrates that, for thymic peptide extracts generally, rigorous independent synthesis has been cautious about clinical benefit.

Safety and risks

Khavinson-group sources describe Thymalin as well tolerated and assert an absence of toxic, allergic, or adverse effects. That characterization should be weighed against its source: it comes largely from the developers and from outlets that Wikipedia editors have flagged as containing promotional content, rather than from independent pharmacovigilance.

General, evidence-based safety considerations include:

• Animal-derived material. Because Thymalin is a bovine (calf) thymus extract, theoretical concerns about hypersensitivity/allergic reactions and animal-source biological material are relevant, as with any tissue-derived preparation.
• Injection-related risks. As an injectable, it carries the usual risks of injection (local reactions, infection if non-sterile).
• Unverified products. Material sold outside Russia's regulated channel is not the registered medicine and may differ in identity, purity, and sterility.

None of this is medical advice. Use of Thymalin, where legal, is a clinical decision made under qualified supervision.

Regulatory status

Thymalin's registration in Russia reflects a national regulatory decision, made under different standards and at a different time than current FDA or EMA review would require. Its absence from FDA and EMA approval is a key fact often omitted from promotional material. In the EU and US it is not an approved medicine.

How it compares

Thymalin is best understood alongside related compounds:

• Thymosin alpha-1 is a single, fully defined 28-amino-acid peptide with a known sequence, structure, and a substantial independent international literature, and is approved as a medicine in a number of countries. Thymalin, by contrast, is a mixture/extract with no single sequence and a far narrower, less independent evidence base. They are both "thymic peptides," but they are not equivalent in definition or evidentiary standing.
• Epitalon (Epithalon/Epithalamin-derived) is another Khavinson bioregulator, a synthetic pineal-associated tetrapeptide marketed for longevity. It shares Thymalin's pattern of bold aging claims resting largely on the same research school with limited independent replication.
• Thymogen (Glu-Trp) is a single synthetic dipeptide isolated from Thymalin and developed separately; it is defined and distinct from the Thymalin extract.

For the broader context of immune-focused peptides, see the Immune support hub.

Common misconceptions

• "Thymalin is a peptide." It is a mixture of thymic peptides (an extract), not a single defined peptide with one sequence.
• "Thymalin and Thymogen are the same." They are not. Thymogen is one synthetic dipeptide (Glu-Trp) isolated from Thymalin; Thymalin is the multi-peptide thymus extract.
• "It's the same as thymosin alpha-1." Thymosin alpha-1 is a single, fully defined peptide with independent international evidence; Thymalin is a less-defined extract with a narrower, less independent evidence base.
• "Because it's registered in Russia, it's FDA/EMA-approved." It is not FDA- or EMA-approved. Russian registration is a separate national decision.
• "The longevity and mortality benefits are proven." The dramatic mortality-reduction figures come from non-blinded studies by the developers' group and have not been independently replicated in rigorous trials.